A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Sikander Ailawadhi; Kevin R. Kelly; Robert A. Vescio; Sundar Jagannath; Jeffrey Wolf; Mecide Gharibo; Taimur Sher; Leyla Bojanini; Maurice Kirby; Asher Chanan-Khan

doi:10.1016/j.clml.2018.08.018

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Sikander Ailawadhi
, Kevin R. Kelly
, Robert A. Vescio
, Sundar Jagannath
, Jeffrey Wolf
, Mecide Gharibo
, Taimur Sher
, Leyla Bojanini
, Maurice Kirby
, Asher Chanan-Khan

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.

Original language	English (US)
Pages (from-to)	29-34
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.clml.2018.08.018
State	Published - Jan 2019
Externally published	Yes

Keywords

Antibody-drug conjugate
Drug-development
Efficacy
Immunotherapy
Monoclonal antibody

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2018.08.018

Cite this

Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J., Gharibo, M., Sher, T., Bojanini, L., Kirby, M., & Chanan-Khan, A. (2019). A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 19(1), 29-34. https://doi.org/10.1016/j.clml.2018.08.018

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. / Ailawadhi, Sikander; Kelly, Kevin R.; Vescio, Robert A. et al.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 19, No. 1, 01.2019, p. 29-34.

Research output: Contribution to journal › Article › peer-review

Ailawadhi, S, Kelly, KR, Vescio, RA, Jagannath, S, Wolf, J, Gharibo, M, Sher, T, Bojanini, L, Kirby, M & Chanan-Khan, A 2019, 'A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia, vol. 19, no. 1, pp. 29-34. https://doi.org/10.1016/j.clml.2018.08.018

@article{b2b365281ee345d8a88c8e8622c0fa03,

title = "A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma",

abstract = "Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.",

keywords = "Antibody-drug conjugate, Drug-development, Efficacy, Immunotherapy, Monoclonal antibody",

author = "Sikander Ailawadhi and Kelly, \{Kevin R.\} and Vescio, \{Robert A.\} and Sundar Jagannath and Jeffrey Wolf and Mecide Gharibo and Taimur Sher and Leyla Bojanini and Maurice Kirby and Asher Chanan-Khan",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = jan,

doi = "10.1016/j.clml.2018.08.018",

language = "English (US)",

volume = "19",

pages = "29--34",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

AU - Ailawadhi, Sikander

AU - Kelly, Kevin R.

AU - Vescio, Robert A.

AU - Jagannath, Sundar

AU - Wolf, Jeffrey

AU - Gharibo, Mecide

AU - Sher, Taimur

AU - Bojanini, Leyla

AU - Kirby, Maurice

AU - Chanan-Khan, Asher

PY - 2019/1

Y1 - 2019/1

N2 - Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.

AB - Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.

KW - Antibody-drug conjugate

KW - Drug-development

KW - Efficacy

KW - Immunotherapy

KW - Monoclonal antibody

UR - https://www.scopus.com/pages/publications/85054865364

UR - https://www.scopus.com/pages/publications/85054865364#tab=citedBy

U2 - 10.1016/j.clml.2018.08.018

DO - 10.1016/j.clml.2018.08.018

M3 - Article

C2 - 30340993

AN - SCOPUS:85054865364

SN - 2152-2650

VL - 19

SP - 29

EP - 34

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 1

ER -

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this